<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01256060</url>
  </required_header>
  <id_info>
    <org_study_id>10-001</org_study_id>
    <nct_id>NCT01256060</nct_id>
  </id_info>
  <brief_title>Intranasal Oxytocin for the Treatment of Children and Adolescents With ASD (OXY)</brief_title>
  <official_title>Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism Spectrum Disorders (ASD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evdokia Anagnostou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Holland Bloorview Kids Rehabilitation Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Anagnostou, Evdokia, M.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extensive data has been accumulated to suggest that central release of oxytocin is important
      for social cognition and function, as well as likely involved in anxiety modulation and
      repetitive behaviors. The principal investigators of this study have previously documented:
      1) an association between Autism Spectrum Disorder and a single nuclear polymorphism of the
      oxytocin receptor gene, 2) ability to measure oxytocin levels in the blood by enzyme
      immunoassay and 3) preliminary data to support safety and efficacy of intranasal oxytocin in
      the treatment of social deficits and repetitive behaviors in adults with autism. A medication
      treatment targeting the core deficits of Autism Spectrum Disorder in childhood is highly
      valuable because it could influence the developmental trajectory and make further
      psychosocial interventions possible. In this context, we propose a small dose finding study
      to confirm that the dose used in the adult study is not more than the maximum tolerated dose
      in youth. `
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>The hypothesis is that the maximum tolerated dose in a range of 0.2-0.4 IU/kg / dose will be 0.4 IU/kg / dose, as was the case in the adult study, given that oxytocin is not stored in body fat and does not depend on liver or renal clearance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Serious Adverse Events</measure>
    <time_frame>24 Weeks</time_frame>
    <description>This will be reported as the number of participants who experienced a serious advert event throughout the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline Levels of Oxytocin in Relation to Either Safety or Treatment Response</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Children and adolescents with lower plasma oxytocin levels at baseline will show treatment related changes in social cognition. Children and adolescents with higher oxytocin plasma levels will show diminished or less dramatic treatment responses and may have more difficulty tolerating the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Levels of Oxytocin During the Trial in Relation to Safety or Treatment Response</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Children and adolescents with minimal changes in plasma level of oxytocin after treatment will be less responsive to treatment. Children and adolescents with atypical patterns of increase in oxytocin may be more sensitive to dose-related tolerability.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in Measures of Social Cognition, Social Function, Repetitive Behaviors, and Anxiety (Baseline to Week 12)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Social Cognition (higher score=positive response)
Let's Face It Skills Battery; i. Matchmaker (0-100); ii. Faces (0-100); iii. Houses (0-100)
Eyes Test (0-28)
Strange Stories (0-16)
Irony and Empathy (0-24)
Social Function
Aberrant Behavior Checklist (0-48) (lower score=positive response)
Behavioral Assessment System for Children (higher score=positive response); i. Social: age 8 to 11 &amp; 15 to 18 (18-69); age 12 to 14 (21-70); ii. Functional: age 8 to 14 (10-66); age 15 to 18 (10-64)
Social Responsiveness Scale (higher score=positive response); male (34-127); female (35-142)
Anxiety (lower score=positive response)
a. Child Symptom Inventory; i. Separation: male (44-106); female (44-101); ii. Generalized: male (40-101); female (41-96)
Repetitive Behaviors (lower score=positive response)
Child Yale-Brown Obsessive-Compulsive Scale (0-20)
Repetitive Behavior Scale (0-129)
Measures insensitive to change will be omitted from results.</description>
  </other_outcome>
  <other_outcome>
    <measure>Measures of Social Function - The Clinical Global Impressions - Social Scale (Baseline to Week 12)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Social Function
a) Clinical Global Impressions - Social Scale (1-7) (lower score=positive response). The results will be reported as the number of participants that were classified as a social responder (achieving a score of 1 or 2 on the scale).</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Intanasal Oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A modified dose finding method will be used to determine safety among four dose levels for Intranasal Oxytocin. Half the dose (0.2 IU/kg /dose) is the minimum dose and two intermediate doses will also be evaluated (0.26 and 0.33 IU/kg / dose) Dose-finding escalations will be done in groups of three patients.Three patients will be studied at the first dose level. If none of these patients experience dose limiting toxicity, the dose will be escalated. If one experiences dose limiting toxicity, up to three more will be accrued at the same level. If none of these experience dose limiting toxicity, the dose will be escalated. If one or more of these experience dose-limiting toxicity, entry at that dose level will be stopped. Up to three more patients will be treated at the next lower dose. If zero out of these experience dose limiting toxicity, an additional three patients will be treated at that dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal Oxytocin</intervention_name>
    <description>We are selecting morning and afternoon dosing to try to influence most hours where youth are in settings with increased potential for social interaction (school, after school). Medication will be administered by the parents before school and early afternoon. All patients will receive their first dose by the study physician to educate parents and themselves on proper administration and determine safety of first dose.</description>
    <arm_group_label>Intanasal Oxytocin</arm_group_label>
    <other_name>Syntocinon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female outpatients 10-17 years of age inclusive.

          2. Meet Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision
             criteria for Autistic Disorder or Asperger's Disorder as established by a clinician
             and supported by the Autism Diagnostic Observation Schedule and the Autism Diagnostic
             Interview - Revised.

          3. Have a Clinician's Global Impression-Severity score â‰¥ 4 (moderately ill) at Baseline.

          4. Verbal Intelligent Quotient &gt;/= 70.

          5. If already receiving stable pharmacological and or non-pharmacologic educational,
             behavioral, and/or dietary interventions, have continuous participation during the
             preceding 3 months prior to Screening and will not electively initiate new or modify
             ongoing interventions for the duration of the study.

          6. Have normal physical examination and laboratory test results at Screening. If
             abnormal, the finding(s) must be deemed clinically insignificant by the Investigator.

          7. The participant and caregiver must be able to speak and understand English
             sufficiently to allow for the completion of all study assessments.

        Exclusion Criteria:

          1. Patients born prior to 35 weeks gestational age.

          2. Patients with any primary psychiatric diagnosis other than autism at Screening.

          3. Patients with current neurological disease, including, but not limited to,
             epilepsy/seizure disorder (except simple febrile seizures), movement disorder,
             tuberous sclerosis, fragile X, and any other known genetic syndromes, or known
             abnormal MRI/structural lesion of the brain.

          4. Pregnant female patients, sexually active female patients on hormonal birth control
             and sexually active females who do not use two types of non-hormonal birth control

          5. Patients with a medical condition that might interfere with the conduct of the study,
             confound interpretation of the study results, or endanger their own well-being.
             Patients with evidence or history of malignancy or any significant hematological,
             endocrine, cardiovascular (including any rhythm disorder), respiratory, renal,
             hepatic, or gastrointestinal disease.

          6. Patients who are sensitive to Syntocinon or any components of its formulation

          7. Patients with one or more of the following: HIV, Hepatitis B virus, Hepatitis C virus,
             hemophilia (bleeding problems, recent nose and brain injuries), abnormal blood
             pressure (hypotension or hypertension), drug abuse, immunity disorder or severe
             depression.

          8. Patients unable to tolerate venipuncture procedures for blood sampling.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evdokia Anagnostou, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Holland Bloorview Kids Rehabilitation Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Suma Jacob, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jessica Brian, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Holland Bloorview Kids Rehabilitation Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wendy Roberts, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sharon Smile, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Holland Bloorview Kids Rehabilitation Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edwin Cook, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Annie Dupuis, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Holland Bloorview Kids Rehabilitation Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margot Taylor, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Holland Bloorview Kids Rehabilitation Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 1R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2010</study_first_submitted>
  <study_first_submitted_qc>December 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2010</study_first_posted>
  <results_first_submitted>January 13, 2015</results_first_submitted>
  <results_first_submitted_qc>April 13, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 15, 2015</results_first_posted>
  <last_update_submitted>July 12, 2016</last_update_submitted>
  <last_update_submitted_qc>July 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Anagnostou, Evdokia, M.D.</investigator_affiliation>
    <investigator_full_name>Evdokia Anagnostou</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Autism Spectrum disorder</keyword>
  <keyword>Oxytocin</keyword>
  <keyword>Clinical Trial</keyword>
  <keyword>Children</keyword>
  <keyword>Pharmacology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from the hospital clinical database, as well as presentations at local conferences and media. Diagnosis was established using the Diagnostic and Statistical Manual, Fourth Edition for an Autism Spectrum Disorder supported by the Autism Diagnostic Observations Schedule and the Autism Diagnostic Interview - Revised.</recruitment_details>
      <pre_assignment_details>Cohort 1 Dosage: 0.20 IU/kg - 3 participants Cohort 2 Dosage: 0.26 IU/kg - 3 participants Cohort 3 Dosage: 0.33 IU/kg - 3 participants Cohort 4 Dosage: 0.40 IU/kg - 6 participants</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>0.2 IU / kg</title>
        </group>
        <group group_id="P2">
          <title>0.26 IU / kg</title>
        </group>
        <group group_id="P3">
          <title>0.33 IU / kg</title>
        </group>
        <group group_id="P4">
          <title>0.4 IU / kg</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intanasal Oxytocin</title>
          <description>A modified dose finding method was used to determine safety among four dose levels. Half the dose (0.2 IU/kg /dose) was the minimum dose and two intermediate doses were also evaluated (0.26 and 0.33 IU/kg / dose) Dose-finding escalations were done in groups of three patients.
Three patients were studied at the first dose level
If none of these patients experienced dose limiting toxicity, the dose was escalated.
If one patient experienced dose limiting toxicity, up to three more patients were accrued at the same level. (a) If none of these patients experienced dose limiting toxicity, the dose was escalated. (b) If one or more experienced dose-limiting toxicity, entry at that dose level would be stopped, the maximum tolerated dose exceeded, and dose escalation would be stopped. Up to three more patients would be treated at the next lower dose. If zero out of three patients experience dose limiting toxicity, an additional three patients were to be treated at that dose.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD)</title>
        <description>The hypothesis is that the maximum tolerated dose in a range of 0.2-0.4 IU/kg / dose will be 0.4 IU/kg / dose, as was the case in the adult study, given that oxytocin is not stored in body fat and does not depend on liver or renal clearance.</description>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intanasal Oxytocin</title>
            <description>Cohort 1 Dosage: 0.20 IU/kg - 3 participants Cohort 2 Dosage: 0.26 IU/kg - 3 participants Cohort 3 Dosage: 0.33 IU/kg - 3 participants Cohort 4 Dosage: 0.40 IU/kg - 6 participants</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD)</title>
          <description>The hypothesis is that the maximum tolerated dose in a range of 0.2-0.4 IU/kg / dose will be 0.4 IU/kg / dose, as was the case in the adult study, given that oxytocin is not stored in body fat and does not depend on liver or renal clearance.</description>
          <units>IU / kg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Serious Adverse Events</title>
        <description>This will be reported as the number of participants who experienced a serious advert event throughout the study.</description>
        <time_frame>24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intanasal Oxytocin</title>
            <description>Number of Participants Experiencing a Serious Adverse Event</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events</title>
          <description>This will be reported as the number of participants who experienced a serious advert event throughout the study.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Levels of Oxytocin in Relation to Either Safety or Treatment Response</title>
        <description>Children and adolescents with lower plasma oxytocin levels at baseline will show treatment related changes in social cognition. Children and adolescents with higher oxytocin plasma levels will show diminished or less dramatic treatment responses and may have more difficulty tolerating the treatment.</description>
        <time_frame>12 Weeks</time_frame>
        <posting_date>12/2016</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Levels of Oxytocin During the Trial in Relation to Safety or Treatment Response</title>
        <description>Children and adolescents with minimal changes in plasma level of oxytocin after treatment will be less responsive to treatment. Children and adolescents with atypical patterns of increase in oxytocin may be more sensitive to dose-related tolerability.</description>
        <time_frame>12 Weeks</time_frame>
        <posting_date>12/2016</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Changes in Measures of Social Cognition, Social Function, Repetitive Behaviors, and Anxiety (Baseline to Week 12)</title>
        <description>Social Cognition (higher score=positive response)
Let's Face It Skills Battery; i. Matchmaker (0-100); ii. Faces (0-100); iii. Houses (0-100)
Eyes Test (0-28)
Strange Stories (0-16)
Irony and Empathy (0-24)
Social Function
Aberrant Behavior Checklist (0-48) (lower score=positive response)
Behavioral Assessment System for Children (higher score=positive response); i. Social: age 8 to 11 &amp; 15 to 18 (18-69); age 12 to 14 (21-70); ii. Functional: age 8 to 14 (10-66); age 15 to 18 (10-64)
Social Responsiveness Scale (higher score=positive response); male (34-127); female (35-142)
Anxiety (lower score=positive response)
a. Child Symptom Inventory; i. Separation: male (44-106); female (44-101); ii. Generalized: male (40-101); female (41-96)
Repetitive Behaviors (lower score=positive response)
Child Yale-Brown Obsessive-Compulsive Scale (0-20)
Repetitive Behavior Scale (0-129)
Measures insensitive to change will be omitted from results.</description>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Oxytocin</title>
            <description>Oxytocin: Intranasal Oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Measures of Social Cognition, Social Function, Repetitive Behaviors, and Anxiety (Baseline to Week 12)</title>
          <description>Social Cognition (higher score=positive response)
Let's Face It Skills Battery; i. Matchmaker (0-100); ii. Faces (0-100); iii. Houses (0-100)
Eyes Test (0-28)
Strange Stories (0-16)
Irony and Empathy (0-24)
Social Function
Aberrant Behavior Checklist (0-48) (lower score=positive response)
Behavioral Assessment System for Children (higher score=positive response); i. Social: age 8 to 11 &amp; 15 to 18 (18-69); age 12 to 14 (21-70); ii. Functional: age 8 to 14 (10-66); age 15 to 18 (10-64)
Social Responsiveness Scale (higher score=positive response); male (34-127); female (35-142)
Anxiety (lower score=positive response)
a. Child Symptom Inventory; i. Separation: male (44-106); female (44-101); ii. Generalized: male (40-101); female (41-96)
Repetitive Behaviors (lower score=positive response)
Child Yale-Brown Obsessive-Compulsive Scale (0-20)
Repetitive Behavior Scale (0-129)
Measures insensitive to change will be omitted from results.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Let's Face It! Skills Battery-Matchmaker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9" lower_limit="-19.3" upper_limit="-2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Let's Face It! Skills Battery-Faces</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.21" lower_limit="-15.26" upper_limit="-3.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Let's Face It! Skills Battery-Houses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.73" lower_limit="-18.5" upper_limit="-2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>The Revised Eyes Test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" lower_limit="-0.82" upper_limit="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strange Stories Task</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" lower_limit="-2.72" upper_limit="0.0008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irony and Empathy Task</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.64" lower_limit="-3.02" upper_limit="-0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aberrant Behavior Checklist</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="0.05" upper_limit="5.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Responsiveness Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" lower_limit="3.8" upper_limit="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Behavioral Assessment System for Children-Social</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.84" lower_limit="-5.31" upper_limit="-0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Behavioral Assessment System for Children-Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.10" lower_limit="-6.23" upper_limit="-1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Child Yale-Brown Obsessive-Compulsive Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.93" lower_limit="0.95" upper_limit="4.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Repetitive Behavior Scale-Revised</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="6.3" upper_limit="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Child and Adolescent Symptom Inventory-Separation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="0.2" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Child and Adolescent Symptom Inventory-General</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" lower_limit="4.0" upper_limit="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Measures of Social Function - The Clinical Global Impressions - Social Scale (Baseline to Week 12)</title>
        <description>Social Function
a) Clinical Global Impressions - Social Scale (1-7) (lower score=positive response). The results will be reported as the number of participants that were classified as a social responder (achieving a score of 1 or 2 on the scale).</description>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Oxytocin</title>
            <description>Oxytocin: Intranasal Oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Measures of Social Function - The Clinical Global Impressions - Social Scale (Baseline to Week 12)</title>
          <description>Social Function
a) Clinical Global Impressions - Social Scale (1-7) (lower score=positive response). The results will be reported as the number of participants that were classified as a social responder (achieving a score of 1 or 2 on the scale).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intranasal Oxytocin</title>
          <description>Oxytocin: Intranasal Oxytocin. Please note that the Adverse Events are not presented per dose level received, as this is not a dose-finding study, it is a modified maximum tolerated dose study. This means that a small number of participants were exposed to increasing dose levels to assess for Adverse Events. It is not meaningful to analyze adverse events by cohorts due to the extremely small sample size.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Tooth Sensitivity/Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infections</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decrease Appetite</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Emotional Lability</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma Attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Itchy Nose</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The sample size is too small to view both safety and efficacy data. The design did not exceed the commonly used 24 IU / dose, so it is not clear that higher doses would not confer benefit. In the absence of placebo, adverse events may be inflated.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Evdokia Anagnostou</name_or_title>
      <organization>Holland Bloorview Kids Rehabilitation Hospital</organization>
      <phone>416-753-6005</phone>
      <email>eanagnostou@hollandbloorview.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

